Deutsche Raises its Price Target on Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) to EUR 21.24 and Maintains a Buy Rating
Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) is among the 11 Cheap Growth Stocks to Buy Right Now.
On February 23, 2026, Deutsche Bank raised its price target on Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) to EUR 21.24 from EUR 19.75 previously and has maintained a Buy rating on the shares. Deutsche Bank cited the improving net interest income and higher return on tangible equity forecasts on Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) as the catalyst behind the price target increase.
Earlier in February, RBC Capital raised its price target on Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) to EUR 20.25 from EUR 19.75 previously and has kept a Sector Perform rating on the shares. Less than two weeks prior to this note, RBC Capital downgraded BBVA to Sector Perform from Outperform, citing BBVA's already-high valuation.
Morgan Stanley also updated its view during the month of February, slightly lowering its price target on Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) to EUR 20 from EUR 20.70 previously, while maintaining an Equal Weight rating on the company.
Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) provides banking and financial services across Spain, Mexico, Turkey, South America, Europe, the United States, and Asia. The company offers traditional retail, wholesale, investment, and transaction banking. It also engages in financial, insurance, asset management, and capital markets businesses, as well as digital banking.
While we acknowledge the potential of BBVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

BCP Investment Corporation Announces Fourth Quarter and Full Year 2025 Financial Results

Global Indemnity Group, LLC Announces Quarterly Distribution

